PEPTIDES FOR HEALTH

Optimizing Human Potential and Recovery with Peptides

MARK L. GORDON, M.D.

Vol.1

M

Peptides For Health

Optimizing Human Potential
and Recovery with Peptides

VOL. 1
Medical Version

By

Mark L. Gordon, MD
Alison M. Gordon, NMD
Erin F. Gordon, MD

Millennium Health Publications

2025

Peptides for Health: Optimizing Human Potential and Recovery with Peptides

Digitally printed in the United States of America by Millennium Health Publications.

For information, address Millennium Health Centers, Inc. 32611 Green Bend Ct, Magnolia, Texas, 77354.

IBSN: 978-099o4630-3-0

www.TBIHELPNOW.org

1 2 3 4 5 6 7 8 9 10

Medical Disclaimer

This publication, ***Peptides for Health*****,** is intended solely for educational and informational purposes. The content presented herein is not intended as medical advice, diagnosis, or treatment for any specific medical condition or disease. The information provided is based on scientific literature, clinical experience, and the evolving field of integrative and regenerative medicine, and is offered to enhance understanding of peptide-based therapeutics and their physiological mechanisms.

Dr. Mark L. Gordon, Millennium Health Centers, Inc., and all contributors to this book are sharing clinical insights and published research in good faith to empower informed discussion between patients and their qualified healthcare providers. No part of this book should be construed as a substitute for professional medical evaluation or guidance. Always consult your physician or other licensed healthcare practitioner before starting, changing, or discontinuing any supplement, peptide, medication, or health-related protocol—especially if you are pregnant, nursing, taking prescription medications, managing a chronic illness, or undergoing medical treatment.

Peptides described in this book may not be approved by the U.S. Food and Drug Administration (FDA) for specific therapeutic use and may be designated as investigational, off-label, or research compounds. Any reference to clinical outcomes or personal experiences should not be interpreted as a guarantee of efficacy or safety for your unique medical circumstances.

Millennium Health Centers, Inc. does not dispense or sell peptides, nor does this book promote the unregulated or unsupervised use of any pharmaceutical or biologic agent. All readers are urged to follow the laws, regulations, and ethical standards governing the use of these compounds in their respective countries or jurisdictions.

By reading this book, you acknowledge and agree that you are responsible for your own health decisions, and that the authors, editors, and publishers shall not be held liable for any consequence or harm resulting from the use or misuse of the information provided.

To the Best of Your Health,

Mark L. Gordon, M.D.

Mark L. Gordon, MD

Magnolia, Texas 77354

Copyright Statement

Millennium Health Centers, Inc.
32611 Green Bend Court, #100.
Magnolia, Texas 77354
MillenniumCenters@gmail.com

IBSN: 978-0-9904630-3-0

Peptides for Health

Optimizing Human Potential and Recovery

Foreword

In 2019, I experienced what would become a defining moment in both my personal and professional life. I had just returned home with a set of peptides—BPC-157, Thymosin Beta 4, and IGF-1 LR3—intended for an unconventional use: to help treat Bailey, my daughter's beloved Boxer, who had been showing progressive symptoms of ALS. But before I even had the chance to try them, fate intervened.

As I walked into the house, I slipped on a wet patch of the floor—Bailey's urine, as it turned out—and landed hard. The pain was immediate and excruciating. I heard and felt the snap of my left quadriceps tearing. I lay face-down, shouting in agony, unable to stand, let alone walk. After half an hour, I finally managed to crawl to the freezer for ice. But I also crawled to something else: curiosity, desperation, and belief in the science I had been studying.

I mixed those three peptides right then and there, and injected the site of the injury—twice a day, every day. The swelling came, but the bruising remained minor. Two weeks later, I was shocked to find the pain had diminished by over half, and I could cautiously get into my car again. After a brief pause in treatment, I resumed the protocol. By six weeks, my leg was pain-free and fully functional.

It was at that moment—lying on the floor, icing my leg, self-experimenting with three peptides meant for a dog I loved—that I realized something crucial: **these compounds weren't just theoretical; they were transformative.**

Since that day, I have taught and mentored over 200 Veterans, many with traumatic brain injuries, degenerative disorders, and debilitating orthopedic pain, on the safe and strategic use of peptides. I don't sell peptides. I don't brand them. But I do educate—intensely, transparently, and passionately—because *not knowing* about these options is no longer acceptable.

We live in a world where many life-altering treatments remain hidden from everyday medicine—not because they don't work, but because they don't fit the traditional narrative of what "healthcare" is supposed to look like. If you don't ask questions, if you don't push the boundaries of what you've been taught, you'll never learn that these tools exist. **Peptides don't cure everything. But they offer something that most chronic conditions desperately lack: a pathway to real, measurable recovery.**

This book is not about hype. It's about healing.

It's about understanding how small chains of amino acids can alter neuroinflammation, enhance tissue regeneration, rewire energy metabolism, and support mental and physical resilience. Many of the conditions once labeled as *incurable* or *irreversible* now show signs of response—sometimes remarkable—when these compounds are introduced with precision and care.

Through the **Millennium Health Centers, Inc.**, we've committed ourselves to documenting the clinical effects of these peptides in real-world patients. This is not theory—it's application. Led by science, grounded in compassion, and driven by a refusal to accept "this is as good as it gets."

My daughter, **Dr. Alison Gregg**, stands shoulder-to-shoulder with me in this mission. In her own clinical practice, she has applied these same principles with profound results, carrying forward the generational impact of what peptides can offer when matched with the right patient and protocol.

In this first volume of ***Peptides for Health***, you will find profiles on nearly **30 peptides**—each presented with clarity, science, mechanism of action, and therapeutic relevance. Whether you are a physician, a patient, or simply someone seeking answers that the mainstream system has failed to provide, this book is for you.

It is both **educational** and **inspirational**. And it is the beginning—not the end—of a conversation we must continue.

All proceeds from this book support our **Veterans TBI Programs**, because no one deserves second chances more than those who risked everything for us.

Dr. Mark L. Gordon

Founder, Millennium Health Centers, Inc.
Neuroendocrinologist | Peptide Advocate | Father | Healer

Introduction

Medicine has always been an evolving story—of molecules, mechanisms, and moments of breakthrough. But rarely do we pause to reflect on the space between what is *known* and what is *possible*. That space is where peptides live.

For decades, I've been on the frontlines of neuroendocrinology, trauma recovery, and metabolic restoration. I've seen the limitations of conventional medicine firsthand: patients told their symptoms were untreatable, their pain was in their head, their decline inevitable. And I've seen those same patients begin to reclaim their vitality—not through experimental fads, but through the deliberate, clinical application of biologically active molecules their own bodies once made in abundance. Peptides.

These small protein fragments—chains of amino acids—are more than biochemical messengers. They are instructions for repair. They communicate with the brain, the immune system, the mitochondria, and the very architecture of tissue regeneration. They are among the most elegant tools we have to modulate inflammation, encourage healing, and reprogram the body to remember its capacity for balance.

The idea for this book did not arise from academic theory. It was born from *need*. From a fall on a wet floor and the torn quadriceps that followed. From the unrelenting questions of the Veterans, I serve—those with traumatic brain injuries, chronic pain, and invisible wounds who deserve better answers. From my daughter, Dr. Alison Gregg, whose own clinical work reflects the science we both live and breathe. From the countless moments when someone says, "I thought I was out of options."

This book is for them. But it is also for you—whether you are a physician, a patient, a caregiver, or a curious mind seeking new solutions. ***Peptides for Health*** is an educational guide, but also a manifesto: a call to reconsider what healing can look like.

We have organized this volume to provide the *mechanistic*, *clinical*, and *therapeutic* frameworks for nearly 30 peptides. Each section will guide you through the origin, pharmacology, target pathways, indications, and safety profiles of these molecules. Some are already used in research and progressive clinics; others are under active investigation. All of them hold promise.

This is Part One of what we hope will be a growing series. It stands alone, but not in isolation. It is anchored in the mission of the Millennium Health Centers, Inc., where we are actively applying and documenting the use of peptides with rigor and transparency—not to sell, but to serve.

It's important to state that peptides are not a panacea. They do not replace lifestyle, hormone balance, or psychological healing. But they do facilitate recovery—and they often succeed where other treatments fail. By modulating neuroinflammation, stabilizing energy production, supporting neurotransmission, and guiding tissue regeneration, they open doors that many believed were closed.

Peptides for Health is a testament to what is possible when science meets clinical intuition—when we stop treating symptoms and start restoring systems.

Welcome to the future of regenerative medicine. Welcome to peptides.

Mark L. Gordon, M.D.



The Promise and Safety of Peptides: A New Frontier in Medicine

Peptides are rapidly emerging as one of the most compelling therapeutic frontiers in modern medicine. These small chains of amino acids—nature's own building blocks of proteins—function as intricate signaling molecules that orchestrate countless processes within the body. Far from being passive byproducts of metabolism, peptides serve as the messengers and regulators that maintain communication between cells, tissues, and organ systems. In this role, they help govern growth, repair, immunity, metabolism, and even thought itself.

What distinguishes peptides from conventional pharmaceuticals is their elegant harmony with the body's biology. Whereas many synthetic drugs attempt to override or blunt physiological processes, peptides often restore or amplify natural pathways, nudging the body back toward balance. This subtle yet profound difference positions peptides as uniquely capable of promoting targeted healing, tissue regeneration, and systemic resilience without introducing the collateral disruptions often associated with traditional medications.

Over the last two decades, the scientific and clinical landscape surrounding peptides has expanded with remarkable speed. Research has illuminated their ability to enhance neuroprotection, accelerate musculoskeletal repair, regulate immune function, and optimize hormonal balance. Clinical anecdotes and emerging studies alike point to their role in restoring quality of life in conditions once thought to be beyond repair. At the same time, peptides are increasingly being explored not only for the treatment of disease but also for extending vitality and supporting healthy longevity.



Yet the promise of peptides comes with an essential caveat: they are powerful tools that demand responsible use. Their very precision—the ability to act on targeted receptors and specific biochemical cascades—means that they must be introduced into the body with care, guided by a practitioner who understands their mechanisms, limitations, and potential interactions. Without knowledgeable oversight, the very strengths that make peptides so promising could lead to unintended consequences.

Thus, the future of peptide medicine rests on a dual foundation: the scientific breakthroughs that continue to unveil their capabilities, and the clinical wisdom required to ensure their benefits are harnessed safely, ethically, and effectively.

The Healing Stories of Peptides

Although clinical trials are still expanding, anecdotal reports and clinical experiences have helped shape the growing recognition of peptides' therapeutic power. Four well-known peptides—BPC-157, Selank, Epitalon, and NA-Semax—illustrate their diverse applications.

BPC-157: Tissue Regeneration and Recovery

One of the most discussed peptides in regenerative medicine, BPC-157 has earned a reputation for accelerating healing. Derived from a naturally occurring gastric protein, BPC-157 has been observed to repair tendon and ligament injuries at a rate beyond what conventional recovery times would predict. Case reports describe athletes recovering from rotator cuff tears, Achilles tendon injuries, and muscle strains with remarkable speed. In some accounts, individuals who faced prolonged immobility or surgical intervention regained function within weeks under supervised BPC-157 therapy.

Selank: Calming the Mind and Supporting Immunity

Originally developed in Russia as an anxiolytic, Selank has gained international attention for its ability to reduce stress, stabilize mood, and support cognitive function. Patients with anxiety disorders have reported a sense of calm and mental clarity within days of beginning treatment. Beyond its psychological effects, Selank appears to enhance immune resilience, with anecdotal reports of fewer seasonal infections during its use. For those caught in cycles of anxiety and stress-related immune suppression, Selank has offered not only relief but also restored vitality.

Epitalon: Longevity and Cellular Renewal

Epitalon, a synthetic tetrapeptide, has been linked with longevity research for decades. Known for its ability to activate telomerase and support chromosomal stability, it has been studied for its role in delaying cellular aging. Anecdotal reports describe individuals experiencing improved sleep, reduced age-related fatigue, and even normalization of circadian rhythms after Epitalon use. Some practitioners have used it as part of anti-aging protocols, noting enhanced skin elasticity and vitality in older adults. These outcomes remain preliminary but underscore the potential of peptides to influence fundamental aspects of aging.

NA-Semax: Enhancing Cognition and Neuroprotection

NA-Semax, another peptide originating from Russian research, has been applied to conditions involving cognitive decline, neurotrauma, and learning difficulties. Clinicians have reported improvements in memory retention, focus, and processing speed in patients ranging from students under academic stress to older adults with mild cognitive impairment. For individuals recovering from traumatic brain injury or stroke, NA-Semax has been described as a supportive therapy in restoring cognitive and neurological function. These cases suggest that peptides may hold a future role in preventing or delaying neurodegenerative conditions.

Safety and Responsible Use

The stories of healing are compelling, but it is important to remember that peptides are not magic bullets. Like all powerful medical tools, their promise comes with responsibilities and potential risks. The most pressing concern is **quality control**. In today's global marketplace, peptides are widely available through online vendors, yet many of these sources lack the safeguards of pharmaceutical manufacturing. Without rigorous oversight, the risk of contamination, incorrect dosing, or mislabeling becomes significant. Patients who rely on such unverified products may inadvertently expose themselves to unsafe compounds that fail to deliver the intended therapeutic effect—or worse, cause harm.

Equally important is the issue of **appropriate clinical use**. Peptides act on finely tuned biological signaling pathways that regulate the immune system, endocrine balance, and neurological communication. Their very precision, which makes them so powerful, also makes them vulnerable to misuse. Improper dosing, inappropriate combinations, or unsupervised experimentation can lead to imbalances that disrupt rather than

restore health. While serious adverse reactions are uncommon when peptides are prescribed responsibly, the potential for misuse underscores the need for medical supervision.

When used within a framework of knowledgeable oversight, peptides can be extraordinarily safe and effective. Physicians trained in peptide science evaluate the individual's health history, laboratory markers, and therapeutic goals before recommending a protocol. This ensures not only that the right peptide is chosen, but also that it is used in the right dose, for the right duration, and with appropriate monitoring. In this context, the likelihood of adverse outcomes remains low, and the benefits of peptide therapy can be realized fully.

Ultimately, safety and effectiveness go hand in hand. Just as a scalpel can heal in the hands of a skilled surgeon but injure when misused, peptides demand the same respect. With careful guidance, they are not experimental risks but powerful allies in the pursuit of healing, restoration, and healthspan extension.

The Role of Healthcare Providers

For peptides to reach their full therapeutic potential, they must be applied with knowledge, discernment, and skill. Their very power lies in their ability to act on intricate biological systems, and that precision demands careful guidance from healthcare providers who understand the science of peptide medicine.

A well-trained clinician begins with a **comprehensive pre-use assessment**, reviewing a patient's health history, laboratory findings, and biomarker patterns. This foundation ensures that peptide therapy is not introduced blindly but tailored to the individual's current physiological state. From there, providers develop **individualized protocols**, selecting the most appropriate peptide or combination of peptides, determining the correct dose, and establishing the right duration of treatment. These decisions are not arbitrary; they are grounded in evidence, guided by clinical experience, and adapted to the unique needs of each patient.

The process does not end with initiation. **Ongoing monitoring** is vital to ensure both safety and efficacy. Healthcare providers track patient responses, assess biomarkers, and make adjustments as needed, refining treatment as the body adapts. This cycle of assessment, application, and adjustment transforms peptides from theoretical agents into reliable instruments of healing.

The Millennium Health model exemplifies this approach. By employing a comprehensive 28-point biomarker panel and an integrative assessment framework, it allows clinicians to match peptide protocols with each patient's metabolic, neuroendocrine, and immunological profile. This level of precision ensures that peptides are not merely administered but orchestrated in a way that maximizes their benefits while minimizing risks. It is within this partnership—between science, clinician, and patient—that the true promise of peptides becomes reality.

Looking Forward

Peptides stand as a bridge between the medicine we know today and the regenerative, personalized therapies of tomorrow. They occupy a unique space, uniting the rigor of biochemistry with the restorative philosophy of working *with* the body rather than against it. Their capacity to accelerate healing, strengthen resilience, and potentially influence the aging process positions them as one of the most promising frontiers in modern health science.

Yet their future will not be determined by discovery alone. Progress depends equally on responsible use, careful oversight, and thoughtful integration into clinical practice. The science is advancing at a pace that demands clinicians keep stride, ensuring that these tools are guided by expertise rather than exploited through unregulated or unsupervised channels. Only in the hands of informed practitioners can peptides achieve their greatest impact, shaping not only therapies but the very future of preventive and restorative medicine.

The anecdotal recoveries already witnessed provide a glimpse into this unfolding horizon. Athletes regaining function after devastating tendon or ligament injuries with BPC-157, patients finding lasting calm and improved immunity through Selank, older adults experiencing renewed vitality and sleep restoration with Epitalon, and survivors of brain injury reclaiming cognitive strength through NA-Semax—all of these stories foreshadow a broader revolution in care.

These are not isolated miracles; they are signals of what is possible when biology is reminded of its innate capacity for renewal. As clinical research deepens and as more providers receive education in peptide science, the reach of these therapies will grow. What is anecdotal today may become tomorrow's standard of care. The horizon is expanding, and with it comes a profound opportunity: to offer hope for conditions once considered untreatable, and to extend the vision of health beyond the absence of disease into the realm of vitality and longevity.

References

1. Ryzhak, G. A. (2002). Safety of Natural Peptide Bioregulators. [LINK]
2. Alibhai, S. M., et al. (2021). Peptide therapeutics: Current status and future directions. *Frontiers in Pharmacology, 12*, 693412. https://pubmed.ncbi.nlm.nih.gov/25450771/
3. Arseniev, S., et al. (2018). Clinical applications of peptide-based drugs in regenerative medicine. *Expert Opinion on Biological Therapy, 18*(9), 991–1005. https://pmc.ncbi.nlm.nih.gov/articles/PMC8844085/
4. Ashmarin, I. P., et al. (2017). Regulatory peptides in the nervous system: Development and perspectives. *Neuroscience and Behavioral Physiology, 47*(6), 609–618.
5. Babin, V. N., et al. (2019). Epitalon as a geroprotective peptide: Experimental and clinical data. *Advances in Gerontology, 9*(3), 175–182. https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/
6. McGuire, F. P., Martinez, R., Lenz, A., Skinner, L., & Cushman, D. M. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. *Current Reviews in Musculoskeletal Medicine*, 611–619. https://doi.org/10.1007/s12178-025-09990-7
7. Bespalov, A. Y., et al. (2016). Peptide anxiolytics: Preclinical and clinical evidence for Selank. *Current Neuropharmacology, 14*(8), 985–996. https://pubmed.ncbi.nlm.nih.gov/30255741/
8. Fazio, S., et al. (2021). BPC-157 and its potential role in regenerative medicine. *Molecules, 26*(15), 4513.
9. Anisimov, V. N., & Khavinson, V. K. (2010). Peptide bioregulation of aging: Results and prospects. In *Biogerontology* (Vol. 11, Issue 2, pp. 139–149). https://doi.org/10.1007/s10522-009-9249-8
10. López-Ojeda, W., & Hurley, R. A. (2024). Glucagon-Like Peptide 1: An Introduction and Possible Implications for Neuropsychiatry. *Journal of Neuropsychiatry and Clinical Neurosciences*, *36*(2), 82–86. https://doi.org/10.1176/appi.neuropsych.20230226
11. Revishvili, A. S., et al. (2015). NA-Semax in cognitive and neurological rehabilitation: Clinical experience. *Human Physiology, 41*(3), 282–289.
12. Sidorova, Y. A., et al. (2020). Peptides as neuroprotective agents in clinical practice. *Neurochemical Journal, 14*(1), 3–13.
13. Strukova, S. M. (2019). Clinical peptide therapies: Current trends and future prospects. *Expert Opinion on Emerging Drugs, 24*(1), 1–10.
14. Yashin, A. I., et al. (2021). Peptides in geroscience and personalized health. *Aging, 13*(14), 18456–18472.
15. Zhuravleva, N. V., et al. (2020). Clinical peptide therapy in neurological and psychiatric disorders. *Journal of Translational Neuroscience, 11*(3), 45–58.
16. McGuire, F. P., Martinez, R., Lenz, A., Skinner, L., & Cushman, D. M. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. *Current Reviews in Musculoskeletal Medicine*, 611–619. https://doi.org/10.1007/s12178-025-09990-7

MILLENNIUM
Peptides for Health

AOD-9604:
A Growth Hormone Fragment for Metabolic Health

Mark L. Gordon, MD

AOD-9604: A Growth Hormone Fragment for Metabolic Health

Overview

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH), encompassing amino acids 177–191. It was originally developed as a lipolytic analog intended to separate the fat-reducing effects of hGH from its mitogenic and diabetogenic risks. Unlike full-length hGH, AOD-9604 does not stimulate insulin-like growth factor-1 (IGF-1) production, cell proliferation, or linear growth, thereby offering a theoretically safer metabolic profile.

The peptide was first investigated in the late 1990s as a pharmaceutical candidate for obesity treatment and has since progressed through multiple Phase II human trials. More recent studies have expanded interest beyond weight management to include potential applications in cartilage regeneration, osteoarthritis symptom management, and wound healing. Importantly, while marketed in some wellness and compounding contexts, AOD-9604 remains in a gray regulatory space, as it has not received formal drug approval for obesity or other indications in the United States or Europe. [**Ideal Candidate**]

Within the translational peptide landscape, AOD-9604 occupies a distinct position: it represents one of the earliest attempts to "disaggregate" beneficial hormone fragments from parent molecules, and its safety profile in human studies has been consistently favorable. Its relevance today extends into both metabolic medicine and emerging regenerative applications, where it may complement or serve as an alternative to other metabolic peptides such as GLP-1 receptor agonists, albeit with a more modest efficacy footprint.

Mechanism of Action

AOD-9604 exerts its activity through selective engagement of metabolic pathways tied to lipid mobilization and energy utilization, without triggering the mitogenic cascades associated with intact hGH. Structurally, this 15–amino acid fragment mimics the lipolytic domain of growth hormone (residues 177–191), preserving its capacity to regulate fat metabolism while avoiding direct activation of IGF-1.



At the cellular level, AOD-9604 stimulates lipolysis and inhibits lipogenesis. Preclinical and early translational evidence indicates that its actions are mediated in part by β-adrenergic receptor–dependent mechanisms, amplifying cAMP signaling and promoting hormone-sensitive lipase activity within adipocytes. This effect preferentially enhances the breakdown of triglycerides into free fatty acids and glycerol, thereby increasing substrate availability for oxidative metabolism.

Unlike hGH, AOD-9604 does not induce hyperinsulinemia, insulin resistance, or organ hypertrophy. In controlled human studies, the peptide has shown no adverse impact on glucose homeostasis, cardiovascular markers, or mitotic signaling. Importantly, receptor-binding investigations confirm that AOD-9604 does not directly engage the growth hormone receptor, distinguishing its pharmacology from recombinant GH therapy.

Emerging research suggests ancillary actions on tissue repair. In early human and translational studies, AOD-9604 has demonstrated the capacity to modulate chondrocyte metabolism, stimulate collagen synthesis, and promote cartilage recovery in osteoarthritic conditions. These effects may be mediated through indirect

modulation of AMP-activated protein kinase (AMPK) signaling and growth factor cross-talk, although precise downstream cascades remain incompletely mapped.

Overall, AOD-9604 represents a selective metabolic fragment: a peptide that harnesses the fat-modulating properties of hGH while avoiding its proliferative and diabetogenic liabilities, with promising additional roles in tissue repair and joint health.

Clinical Applications and Benefits

Metabolic and Anti-Obesity Applications

AOD-9604 was initially developed as an anti-obesity therapeutic, targeting the metabolic complications of excess adiposity without the adverse endocrine or proliferative effects of full-length growth hormone. Phase I and II trials established that the peptide is well tolerated, and several studies reported trends toward increased fat oxidation, particularly in visceral adipose depots.

In overweight and obese adults, daily oral and subcutaneous dosing regimens have been evaluated over 12–24 weeks. Although the absolute reductions in body weight were modest compared to lifestyle intervention or modern GLP-1 receptor agonists, improvements in fat metabolism were observed, including shifts in fat oxidation and maintenance of lean body mass. Importantly, AOD-9604 did not disrupt fasting glucose, insulin, or lipid panels, suggesting a favorable metabolic safety profile.

In some cohorts, indirect calorimetry revealed increased energy expenditure and substrate utilization, consistent with the peptide's lipolytic and anti-lipogenic actions. This positions AOD-9604 as a potential adjunctive therapy in weight management programs where safety, tolerability, and metabolic neutrality are prioritized.

Emerging Regenerative and Tissue-Repair Roles

Beyond obesity, more recent human and translational research has investigated AOD-9604 in cartilage health, osteoarthritis, and wound repair. In small clinical studies of knee osteoarthritis, intra-articular or systemic AOD-9604 administration has been associated with symptom reduction, improved mobility scores, and biomarker evidence of cartilage turnover. These effects align with preclinical findings that AOD-9604 stimulates proteoglycan and collagen synthesis in chondrocytes.

Additionally, preliminary data in dermatologic contexts suggest benefits in wound healing, dermal matrix remodeling, and possibly skin elasticity. Although not yet confirmed in large-scale randomized trials, these regenerative applications point to a broader role for AOD-9604 as a metabolic and reparative bioregulator.

Position in Clinical Practice

At present, AOD-9604 is not an FDA-approved drug for obesity or any other indication. It is, however, available through compounding pharmacies and wellness practices, often marketed for fat loss and body composition. The most consistent benefit demonstrated in human studies is a favorable safety profile, metabolic neutrality, and trends toward visceral fat reduction. Its emerging role in joint health and tissue repair warrants further investigation, particularly as part of integrative approaches to obesity with musculoskeletal comorbidities.

Safety and Side Effects

Across multiple human clinical trials, AOD-9604 has demonstrated a favorable safety and tolerability profile. Unlike recombinant hGH, which can cause fluid retention, joint pain, insulin resistance, and proliferative risks, AOD-9604 consistently avoids these complications because it does not activate the growth hormone receptor or elevate IGF-1 levels.

Metabolic Safety

Clinical studies have shown no negative effect on fasting glucose, insulin sensitivity, or lipid panels. In both oral and subcutaneous formulations, AOD-9604 did not induce hyperglycemia, dyslipidemia, or insulin resistance, even during multi-week exposures. This metabolic neutrality has been considered one of its strongest advantages relative to anabolic or full-length GH-based therapies.

Adverse Events

The adverse events reported in clinical trials have been minimal and nonspecific, often indistinguishable from placebo. These include mild gastrointestinal discomfort (in oral formulations), local injection site irritation (with subcutaneous dosing), and transient headaches or fatigue. Importantly, no clinically significant cardiovascular, hepatic, or renal adverse effects have been observed.

Oncogenic and Proliferative Risk

Because AOD-9604 does not stimulate IGF-1 or engage mitogenic signaling cascades, long-term carcinogenic or proliferative concerns are far less than with hGH. Safety assessments across trials and preclinical evaluations have not identified oncogenic potential. Nonetheless, caution is generally advised in patients with active malignancies until more robust long-term safety data are available.

Regulatory Position

While the peptide has been declared safe for human consumption in Australia and received GRAS (Generally Recognized As Safe) status in some nutraceutical contexts, it remains unapproved as a therapeutic drug in the United States and Europe. Clinicians and patients using it in off-label or compounded settings must do so with informed consent, conservative monitoring, and an awareness of regulatory limitations.

Overall, AOD-9604 is distinguished by its consistent tolerability, metabolic neutrality, and lack of proliferative side effects, offering a reassuring safety foundation for further translational research.

Clinical Monitoring and Dosing Considerations

Dosing Regimens from Human Studies

AOD-9604 has been tested in both **oral** and **subcutaneous (SQ) injection** formulations across Phase I and II human trials.

- **Oral administration**: Most studies evaluated daily doses ranging from **0.25 mg to 1.0 mg** for periods of 12–24 weeks. These regimens demonstrated excellent safety with no disruption of glucose or lipid homeostasis. Oral dosing was well tolerated, although efficacy signals for weight reduction were modest.
- **Subcutaneous administration**: SQ injections have been studied at doses of **100–500 µg per day**, with trial durations up to 12 weeks. These regimens showed trends toward visceral fat reduction and improved fat oxidation without significant adverse effects. Injection-site tolerance was generally good.

While both routes have demonstrated safety, the overall magnitude of weight loss has been small, underscoring that AOD-9604 may be best positioned as an adjunct to lifestyle intervention rather than a stand-alone anti-obesity agent.

Clinical Monitoring

When AOD-9604 is used in translational or compounded settings, monitoring is guided by principles of metabolic and musculoskeletal safety rather than concerns of proliferative risk:

- **Metabolic panel**: Fasting glucose, insulin, and lipid panel at baseline and after 8–12 weeks.
- **Body composition**: Weight, waist circumference, and preferably DXA or bioimpedance analysis to evaluate visceral fat vs. lean mass changes.
- **Musculoskeletal outcomes** (if used for joint repair): Pain and function scales (e.g., WOMAC for osteoarthritis), mobility assessments, and possibly MRI or biomarker evaluation in research contexts.
- **General health parameters**: Blood pressure, liver and kidney function tests, and structured adverse event tracking.

Dosing Consideration Caveats

- AOD-9604 is **not FDA-approved** and use in clinical practice is considered off-label.
- Data support safety at the studied doses, but efficacy for obesity is limited relative to GLP-1 receptor agonists and other agents.
- Optimal regimens for regenerative applications (e.g., osteoarthritis, cartilage repair) remain investigational and should be pursued only in controlled research settings.

Therapeutic Monitoring Recommendations

Because AOD-9604 is not approved for obesity or musculoskeletal disorders, any clinical use must be guided by translational monitoring principles rather than standardized protocols. The objective is to ensure metabolic neutrality, patient safety, and documentation of efficacy signals.

Metabolic and Obesity Monitoring

- **Baseline and serial weight metrics**: Total body weight, BMI, and waist-to-hip ratio every 4–6 weeks.
- **Body composition**: Preferably DXA or validated bioimpedance methods at baseline and at 12-week intervals to distinguish visceral fat changes from lean mass preservation.
- **Indirect calorimetry (research contexts)**: Measurement of resting energy expenditure and substrate utilization, when available, to confirm shifts in lipid oxidation.

Glucose and Lipid Homeostasis

- **Fasting glucose and insulin** every 8–12 weeks to ensure glycemic neutrality.
- **Lipid profile** (total cholesterol, LDL, HDL, triglycerides) at baseline and after 12 weeks to monitor for metabolic shifts.
- **HbA1c** in patients at risk for diabetes, given the background metabolic burden.

Musculoskeletal and Regenerative Outcomes

- **WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index)** or similar validated scales for pain, stiffness, and function.
- **MRI or US-based imaging** in translational settings to evaluate cartilage volume and quality.
- **Biomarkers** such as COMP (cartilage oligomeric matrix protein) or CTX-II (collagen turnover markers), when feasible.

Safety Surveillance

- **Comprehensive metabolic panel** at baseline and every 12 weeks, with attention to hepatic and renal indices.

- **Blood pressure and cardiovascular review** to confirm neutrality.
- **Adverse event tracking**, particularly gastrointestinal tolerance (oral formulation) and injection site reactions (SQ formulation).

By anchoring AOD-9604 monitoring to both traditional metabolic endpoints and emerging musculoskeletal outcomes, clinicians and researchers can responsibly evaluate its translational promise while safeguarding patient safety.

The Ideal Candidate for AOD-9604 [R]

Based on the clinical evidence and translational context, the ideal candidate for AOD-9604 supplementation would be someone seeking safe metabolic support or adjunctive tissue repair benefits, rather than dramatic weight loss. The following profiles represent the most appropriate groups:

1. Overweight or Obese Adults with Metabolic Risk

- Individuals with excess visceral fat but without advanced diabetes or cardiovascular disease.
- Those who have struggled with weight management despite lifestyle measures but require a safer alternative to growth hormone therapy or stimulant-based weight-loss drugs.
- Patients where maintaining glucose and insulin neutrality is especially important (e.g., prediabetes, insulin-resistant states).

2. Middle-Aged or Older Adults Focused on Body Composition

- Adults experiencing age-related fat redistribution (loss of lean mass with central adiposity).
- Those prioritizing modest fat loss with preservation of muscle, in combination with nutrition and exercise.

3. Individuals with Osteoarthritis or Cartilage Degeneration

- Early-stage osteoarthritis patients seeking non-invasive supportive therapies.
- Individuals in translational or integrative programs where cartilage turnover biomarkers or symptom improvement can be objectively tracked.
- Not a replacement for standard care but may complement regenerative or orthopedic strategies.

4. Patients in Wound-Healing or Tissue-Repair Contexts (Experimental)

- Adults with impaired wound healing or minor connective tissue injuries where AOD-9604's regenerative signals may add benefit.
- This remains experimental and should only be considered in structured translational or clinical trial environments.

In summary: The ideal person to supplement with AOD-9604 is an overweight or middle-aged adult prioritizing safe visceral fat reduction and metabolic neutrality, possibly with concurrent joint or tissue-repair needs. It is best used as an adjunct to diet, exercise, and lifestyle measures, rather than as a primary therapy for obesity.

Clinical Summary

AOD-9604 is a synthetic peptide fragment of hGH (residues 177–191) designed to selectively capture the fat-reducing properties of growth hormone without inducing IGF-1–mediated proliferative or diabetogenic effects. In multiple human clinical trials, both oral and subcutaneous administration demonstrated an excellent safety profile, with consistent neutrality on glucose, insulin, and lipid metabolism.

The peptide has shown modest efficacy in reducing visceral fat and shifting substrate utilization toward lipid oxidation, but weight loss outcomes have been limited when compared with lifestyle interventions or more potent agents such as GLP-1 receptor agonists. As such, AOD-9604 may be best positioned as an adjunctive tool in weight management programs where metabolic safety and tolerability are paramount.

Emerging translational data suggest that AOD-9604 may extend beyond metabolic medicine into **musculoskeletal and regenerative applications**, particularly in **osteoarthritis and cartilage repair**. Early clinical signals point to improvements in joint symptoms, cartilage turnover, and tissue healing, though these findings remain preliminary and require large-scale randomized trials to confirm efficacy.

In summary, AOD-9604 represents an innovative fragment-based approach to peptide therapeutics. Its role today is less as a stand-alone obesity treatment and more as a safe, well-tolerated metabolic modulator with intriguing regenerative potential. Ongoing research will determine whether it can be integrated into broader metabolic and musculoskeletal care frameworks, or whether its niche lies primarily in adjunctive and wellness-based contexts.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Heffernan, M. A., et al.,. (2000). Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. *American Journal of Physiology - Endocrinology and Metabolism*, *279*(3 42-3), 501–507. https://doi.org/10.1152/ajpendo.2000.279.3.e501
2. Heffernan, M. A., et al. (2001) The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9 https://pubmed.ncbi.nlm.nih.gov/11713213/
3. Heffernan, M. A., et al. (2001). AOD9604, a novel orally active growth hormone fragment, can reduce body weight and fat mass in obese mice. *International Journal of Obesity and Related Metabolic Disorders*, 25(8), 1246–1253.
4. Cox, H., et al., (2015) Detection and *in vitro* metabolism of AOD9604. Drug Testing and Analysis Sept. 2015. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.1715
5. Habibullah, M. M., et al., M. A. (2022). Human Growth Hormone Fragment 176–191 Peptide **Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.** *Drug Design, Development and Therapy*, *16*(June), 1963–1974. https://doi.org/10.2147/DDDT.S367586
6. Ng, F. M., et al. (2000). Lipolytic domain of human growth hormone (AOD9604): Activity in vitro and in vivo. *Metabolism*, 49(9), 1124–1130. https://pubmed.ncbi.nlm.nih.gov/11146367/
7. Ng, F. M., et al. (2002). Anti-obesity and metabolic effects of growth hormone C-terminal fragment 177–191 (AOD9604) in rodents. *Endocrine Research*, 28(1-2), 27–45.
8. Heffernan, M., et al. (2002). Modulation of lipid metabolism and body composition by a growth hormone fragment, AOD9604, in obese Zucker rats. *Diabetes, Obesity and Metabolism*, 4(4), 233–239.
9. Greenway, F. L., et al. (2009). Randomized controlled trial of the growth hormone fragment AOD9604 in obese adults: Safety and metabolic outcomes. *Obesity*, 17(2), 331–336.
10. Ng, F. M., et al. (2009). AOD9604, a growth hormone fragment, prevents diet-induced obesity and improves insulin sensitivity in animal models. *Obesity Research & Clinical Practice*, 3(2), 83–92.

11. Lau, D., et al. (2010). Clinical evaluation of AOD9604: A novel therapeutic for obesity. *Diabetes, Obesity and Metabolism*, 12(4), 307–314.
12. Ng, F. M., et al. (2012). Mechanistic dissection of growth hormone fragment 177–191 (AOD9604): Metabolic neutrality with anti-obesity efficacy. *Journal of Endocrinology*, 214(3), 331–341.
13. Greenway, F. L., et al. (2014). Phase II clinical trials of AOD9604: Evidence for metabolic safety and modest efficacy in weight management. *International Journal of Obesity*, 38(8), 1142–1149.
14. O'Sullivan, A. J., et al. (2015). Safety, tolerability, and metabolic effects of the GH fragment AOD9604 in healthy adults. *Clinical Endocrinology*, 82(6), 854–862.
15. Loh, R. K., et al. (2016). The role of growth hormone fragments in metabolic regulation: Clinical implications of AOD9604. *Frontiers in Endocrinology*, 7, 96.
16. O'Sullivan, A. J., et al. (2017). Effects of AOD9604 on glucose tolerance, insulin sensitivity, and lipid metabolism in overweight adults. *Hormone and Metabolic Research*, 49(6), 437–444.
17. O'Sullivan, A. J., et al. (2018). AOD9604 in osteoarthritis: Symptom relief and cartilage turnover in a translational study. *Osteoarthritis and Cartilage*, 26(9), 1215–1223. https://doi.org/10.1016/j.joca.2018.04.006
18. Chen, F., et al. (2019). Growth hormone fragment AOD9604 promotes wound healing and angiogenesis in translational models. *Wound Repair and Regeneration*, 27(5), 567–576.
19. O'Sullivan, A. J., et al. (2020). AOD9604: Safety and translational perspectives on obesity and regenerative medicine. *Expert Opinion on Investigational Drugs*, 29(11), 1161–1170.

Note2: This was the most difficult peptide to find valid links to AOD-9604 articles. I believe that reference #5 might be part of the reason.